No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
J&J Reports Results of Phase 3 GALAXI Study For Tremfya® (guselkumab)
On 21 May 2024, Johnson & Johnson announced results of the GALAXI 2&3 clinical studies of patients with moderate to severe Crohn’s Disease (CD). The study, sponsored by Janssen Research & Development, showed that Tremfya® (guselkumab) resulted in...